Semaglutide half-life & pharmacokinetics

Reported half-life

Approximately 165-184 hours (~7 days) plasma half-life through covalent fatty-acid binding to circulating serum albumin. Supports once-weekly subcutaneous dosing for the injectable formulations (Ozempic, Wegovy) and once-daily oral dosing with absorption-enhancing co-formulation (Rybelsus). The 7-day half-life is materially longer than liraglutide (~13 hours) and exenatide (~2.5 hours), reflecting the C18 fatty diacid modification specifically engineered for albumin retention.

The half-life and pharmacokinetic profile of Semaglutide reported above is drawn from the published pre-clinical literature. Plasma half-life describes the time taken for the circulating concentration to fall by half after a single dose; tissue half-life — which may be longer for peptides retained in specific organs or matrices — is a distinct and often more relevant parameter for healing research, where the duration of exposure at the injury site matters more than the systemic exposure profile.

Routes of administration studied

• Subcutaneous injection (Ozempic, Wegovy — weekly licensed dosing)
• Oral tablet (Rybelsus — daily licensed dosing, co-formulated with SNAC absorption enhancer)

Different routes produce materially different pharmacokinetic profiles for the same peptide. Subcutaneous administration generally produces flatter, more sustained plasma profiles than intravenous bolus dosing; intraperitoneal administration (common in rodent models) is not directly translatable to human routes; oral administration faces the additional challenge of luminal and brush-border peptidase degradation, which is why most research peptides have very low oral bioavailability without protective formulation.

Drug class

Long-acting glucagon-like peptide-1 receptor (GLP-1R) agonist; MHRA-licensed medicinal product for type-2 diabetes and chronic weight management.

Mechanism context

Half-life interpretation depends on the underlying mechanism. Semaglutide acts as follows:

Yes — Ozempic is a peptide. Its active ingredient, semaglutide, is a synthetic analogue of the human gut hormone GLP-1 (glucagon-like peptide-1), sharing 94% sequence homology with native GLP-1, and it works by selectively binding to and activating the GLP-1 receptor — the same receptor targeted by the natural hormone (UK Summary of Product Characteristics; FDA prescribing information). The peptide backbone is produced in yeast (Saccharomyces cerevisiae) by recombinant DNA technology, then chemically modified at amino-acid position 8 to resist degradation by the DPP-4 enzyme and at lysine 26 with a C18 fatty-diacid chain that binds circulating albumin — extending the plasma half-life to roughly one week and enabling once-weekly subcutaneous dosing. Ozempic is MHRA-licensed in the UK for type-2 diabetes; the same molecule, at a higher dose, is licensed as Wegovy for weight management.

See the full Semaglutide research profile for the complete mechanism summary, history, study citations, and references.

Practical considerations

Short plasma half-life does not necessarily mean short duration of biological effect. Many peptides — including BPC-157, GHK-Cu, and the thymosin-derived compounds — exhibit tissue retention or mechanistic effects (gene expression, signalling cascades) that outlast plasma exposure by hours to days. The pharmacological half-life and the biological-effect half-life are distinct parameters that must both be specified in any rigorous research design. Repeated-dose protocols should account for accumulation only where tissue half-life is genuinely long; for most peptides with short plasma half-life and rapid degradation, accumulation is not a practical concern.

For dose ranges in published research, see the dosing reference page. For reconstitution guidance, see the reconstitution reference page.